Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer and Perlegen Ink SNP Collaboration on Metabolic Syndrome

NEW YORK, Jan. 7 (GenomeWeb News) - Perlegen Sciences and Pfizer have started a research collaboration to discover genetic markers for metabolic syndrome, Perlegen said today.

 

Perlegen, located in Mountain View, Calif., will use its genotyping technology to analyze thousands of patient samples for SNPs associated with metabolic syndrome. Pfizer will provide Perlegen with research funding and milestone payments and license the technology. The companies will share any therapeutic and diagnostic rights resulting from the collaboration.

 

Metabolic syndrome greatly increases the risk of developing cardiovascular disease and type 2 diabetes.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.